IMMUNE CELL ENGINEERING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Market News

Recent Developments:

New product launches:

• On August 10, 2023, Astellas Pharma, Inc., a pharmaceutical company and Poseida Therapeutics, a clinical stage company entered into a strategic investment agreement to further support the development of cell therapies for cancer. Astellas will be investing a total of US$ 50 million and a one-time US$ 25 million payment for a right of exclusive negotiation and first refusal to license one of Poseida’s clinical-stage programs, P-MUC1C-ALLO1, which is an allogeneic chimeric antigen T cell (CAR-T) cell therapy in development for multiple solid tumor indications.
• On July 19, 2023, Integrated Biosciences, a biotechnology company, announced a drug discovery platform that enables precise control of the integrated stress response (ISR), a biological pathway that is activated by cells in response to a wide variety of pathological and aging-associated conditions,  to use synthetic biology, and in particular ontogenetic, to control age-related cellular signaling pathways. This technology allows for novel drug discovery efforts, allowing us to query specific aspects of cellular biology that produce faster, on-target drug screens with built-in mechanism of action validation.
• In December 2022, Ferring B.V., a biopharmaceutical company, announced that the U.S. Food and Drug Administration had approved Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating (cannot multiply in human cells) adenoviral vector based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
• In April 2022, Thermo Fisher Scientific, Inc., a biotechnology company, launched the new Gibco CTS DynaCellect Electroporation System for more consistent and efficient delivery of molecules into hard-to-transfect cells. This improved cell engineering workflow efficiency in cell line development and cell therapy manufacturing.
• In December 2021, Novartis, a pharmaceutical company, announced the launch of T-Charge, its next-generation CAR-T platform, which can be used as the foundation for various new investigational CAR-T cell therapies in the company’s pipeline. The T-Charge platform helps in developing CAR-T cell therapy products with greater proliferative potential and fewer exhausted T cells.

• In March 2021, Beckman Coulter, a biotechnology company, launched the CytoFLEX SRT cell sorter to automate and standardize sorting during cell engineering processes for reproducibility.

Acquisition and partnerships:

• On September 18, 2023, Lupagen Inc., a pioneer in cell and gene therapy delivery, announced a new development and supply agreement partnership with Fresenius Kabi, a global leader in injectable medicines, infusion technology, and clinical nutrition, to advance bedside cell and gene therapy. Under the partnership, Fresenius Kabi will provide expertise from its transfusion medicine unit to optimize Lupagen’s platform for delivering cell and gene therapy treatments at the bedside of patients suffering from many conditions including cancer and others.
• On April 11, 2023, Discovery Life Sciences, a manufacturer of biomarkers, acquired ReachBio Research Labs (ReachBio), a company specializing in cell-based assays, predictive hematotoxicity, and drug screening services. This acquisition will allow Discovery to scale its consolidated drug discovery and preclinical development offerings to give customers access to a broader range of innovative and specialized cell biology services.
• In December 2022, Gilead Sciences, Inc., a pharmaceutical company,  announced a collaboration with Arcellx, Inc., a biotechnology company, to co-develop and co-commercialize Arcellx, Inc.’s lead late-stage product candidate named CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma
• In February 2021, Charles River Laboratories acquired Cognate Bio Services to expand its cell and gene therapy capabilities and fully integrate CDMO offerings.
• In November 2020, Catalent Inc., a biotechnology company, acquired Bone Therapeutics' subsidiary Skeletal Cell Therapy Support to expand its capabilities in cell therapies and strengthen its expertise in GMP manufacturing of MSCs.

• In March 2020, FUJIFILM Corporation acquired Biogen's manufacturing facility in Denmark to expand its capacity to produce gene therapies and cell therapies.